Furthermore, suppression of Nek2 results in the decreased viability of cancer cells in solid cancers, like breast cancer [12], non-small cell lung cancer [13], colorectal cancer [14], ovarian cancer [15], and liquid cancers like myeloma [9]. This evidence concerns the gene NEK2 and breast carcinoma.